M.D., Deputy Director for Molecular Pathology and Genomics, Swedish Cancer Institute
Biography
Dr. Anna Berry is the Deputy Director for Molecular Pathology and Genomics at the Swedish Cancer Institute, where she also serves as the Scientific Director of the Personalized Medicine Program. She is a graduate of the University of Nebraska Medical Center, and completed her post-graduate training at SUNY Upstate Medical University, the Medical College of Virginia, and the National Cancer Institute. Dr. Berry is Board Certified in Molecular Genetic Pathology, Cytopathology, Anatomic Pathology and Clinical Pathology, and served previously as the Director of Molecular Pathology and the Director of the Molecular Genetic Pathology fellowship training program at UCSF. Her clinical focus is making genomic technologies accessible to patients, and integrating genomic data into patient care. She serves on several national committees, including the Personalized Healthcare Committee of the College of American Pathologists, and participates in several national genomics task forces.
Session Abstract – PMWC 2020 Silicon Valley
Track 4 - January 22 2.00 P.M.-3.00 P.M.
The purpose of clinical decision support tools and systems is to provide accurate, timely information to the clinical team and patient to help inform about a patient’s care. Clinical decision support can potentially lower costs, improve patient outcomes and efficiency, and reduce patient inconvenience. In this session, we will hear from representatives from major healthcare organizations about their perspectives and experiences when adopting/implementing clinical decision support.
